Pfizer announced July 29 that it will combine its generics and off-patent drugs unit Upjohn with EpiPen-maker Mylan.
Source: The Associated Press
Pfizer Inc. kicked off a heavy earnings week for the healthcare industry by announcing that it will combine its generics and off-patent drugs unit Upjohn with Mylan NV, possibly creating a powerhouse company in the low-cost drug market.
The combination of EpiPen-maker Mylan and Upjohn, which is devoted to Pfizer's off-patent drugs like Viagra and Lipitor, is estimated to pull in sales of almost $20 billion in 2020 and $22 billion in 2021, according to Leerink analyst Ami Fadia.
Mylan President Rajiv Malik said the combined company would own about a third of all generics and about 15% of the U.S. generic market.
"You have a portfolio that anywhere in the world can play the entire spectrum of healthcare," Malik said. "You have generics, you have brands, you have [over-the-counter], you have biologics — and we can twist and turn that by market and adjust it to local market needs, but it's a very powerful mix of portfolio."
Upjohn President Michael Goettler, who is likely to become the new company's CEO, said on an investor call that Mylan will be particularly beneficial in China, where the new company will invest its combined expertise.
"China, for the new company, is a very large opportunity, a huge market — 1.4 billion people, a huge unmet medical need and already the second-largest pharmaceutical market," Goettler said. "We have incredible capabilities in China, and Pfizer has built them over 40 years."
Story: Pfizer off-loads generics division to Mylan, creating estimated $20B powerhouse
More coverage: Pfizer to become leaner with Mylan generics deal, increase focus on innovation
Chart of the week
Story: Canadian cannabis sales continue to grow in 1st full quarter of legal sales
Trump administration proposes 2 drug importation pathways
The U.S. Department of Health and Human Services released an action plan that could allow states and pharmaceutical companies to import pharmaceutical drugs from Canada and other countries.
Following Trump order, Medicare agency proposes hospital price transparency rule
The Centers for Medicare and Medicaid Services proposed a new rule that will require hospitals and other healthcare providers to make rates privately negotiated with insurance companies public.
HHS Secretary Alex Azar told reporters July 31 that the new drug importation action plan is part of the Trump administration's larger strategy to lower rising drug prices.
Source: The Associated Press
Experts: Ebola a concern, but pandemic flu, 'disease X' more worrisome
With an ongoing Ebola outbreak in Africa, an epidemic of measles that has spread across the U.S. and around the world, and what may be another bad flu season fast approaching, the American infectious disease community has not rested easy in recent months, a top U.S. official said.
'We have all seen this movie before': N.H. Medicaid work rules struck down
A federal judge has struck down New Hampshire's Medicaid work requirements policy, delivering yet another loss to the controversial policy touted by the Trump administration as a way to lift Medicaid recipients out of poverty.
M&A activity shifts from gene therapies to pipeline-boosting biotechs in Q2
Although first-quarter M&A activity in the healthcare sector was dominated by cell and gene therapy deals, the second quarter saw a greater focus on biotechnology acquisitions as companies moved to boost their product pipelines, an analysis of S&P Global Market Intelligence data shows.
Healthcare companies are reporting second-quarter earnings, with Merck & Co. Inc., Sanofi and Eli Lilly and Co. in the spotlight this week. The S&P Global Market Intelligence Healthcare news team takes a look at companies’ performance and the remaining half to come.
Pharma executives get pressed on M&A during Q2 calls amid megadeal mania
Healthcare companies are reporting results for the second quarter amid a flurry of megamergers, and Wall Street wants to know who is next.
Merck CEO 'not interested' in megadeal fray as sales of Keytruda, Gardasil surge
Merck CEO Ken Frazier is "not interested" in participating in the crush of pharmaceutical megadeals seen so far in 2019.
Eli Lilly growth trend continues, but competition puts pressure on Trulicity
Eli Lilly's first half was defined by the loss of exclusivity on erectile dysfunction drug Cialis and the withdrawal of failed sarcoma drug Lartruvo, but the pharmaceutical giant notched its 15th consecutive quarter of worldwide revenue growth due to pipeline gains and key regulatory approvals in the second quarter.
Sanofi to file more than 10 drugs in China by year-end, drops 7 early assets
Sanofi, the French drugmaker that recently appointed Paul Hudson of Novartis AG its next CEO, intends to file more than 10 drugs for approval in China by year-end after second-quarter sales jumped by 17% in the region, making it the company's second-largest global market.
Takeda upbeat on plasma, cancer therapies despite loss-making Q1
Takeda Pharmaceutical Co. Ltd. maintained an optimistic outlook for a certain type of plasma therapy over the next quarter and highlighted the strong ongoing performance of cancer drug Ninlaro in China, after posting a loss for the fiscal first quarter ended June 30.
HCA Healthcare misses estimates on key earnings metrics; stock drops over 9%
HCA Healthcare Inc.'s second-quarter earnings results missed consensus estimates for multiple key metrics. The hospital giant's stock was down by more than 9% after the market opened July 30.